Vicki L. Sato Sells 1,020 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 1,020 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the sale, the director now directly owns 111,056 shares in the company, valued at $3,331,680. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $29.63 on Thursday. Denali Therapeutics Inc. has a 1 year low of $14.56 and a 1 year high of $33.33. The company has a market cap of $4.26 billion, a P/E ratio of -10.74 and a beta of 1.40. The stock’s fifty day moving average price is $28.14 and its 200-day moving average price is $23.88.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the company earned ($0.72) earnings per share. On average, sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.66 earnings per share for the current year.

Analysts Set New Price Targets

DNLI has been the topic of a number of recent analyst reports. Bank of America increased their price target on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Jefferies Financial Group increased their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Wedbush reduced their target price on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Finally, Citigroup lifted their price target on Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $38.90.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. EP Wealth Advisors LLC bought a new position in Denali Therapeutics in the 1st quarter worth $831,000. Edgestream Partners L.P. purchased a new stake in shares of Denali Therapeutics during the 1st quarter worth approximately $2,301,000. Bayesian Capital Management LP purchased a new position in shares of Denali Therapeutics in the 1st quarter worth $447,000. Swiss National Bank increased its stake in Denali Therapeutics by 0.7% during the first quarter. Swiss National Bank now owns 218,200 shares of the company’s stock worth $4,477,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Capital Research Global Investors increased its position in shares of Denali Therapeutics by 107.9% during the 1st quarter. Capital Research Global Investors now owns 6,049,957 shares of the company’s stock valued at $124,145,000 after purchasing an additional 3,140,429 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.